CombiGene AB (publ) (COMBI.ST)
SEK 2.7
(-0.74%)
SEK 2.7
(-0.74%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -21.29 Million SEK | -101.99% |
| 2022 | -19.2 Million SEK | -226.62% |
| 2021 | 15.16 Million SEK | 81.98% |
| 2020 | 8.33 Million SEK | -39.7% |
| 2019 | 13.81 Million SEK | 181.73% |
| 2018 | -16.9 Million SEK | -79.72% |
| 2017 | -9.4 Million SEK | -29.77% |
| 2016 | -7.25 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -693 Thousand SEK | 95.45% |
| 2024 Q1 | -15.23 Million SEK | -71.33% |
| 2023 Q1 | -13.74 Million SEK | 50.33% |
| 2023 Q4 | -8.89 Million SEK | -7.49% |
| 2023 Q3 | -8.27 Million SEK | -7.46% |
| 2023 FY | -38.78 Million SEK | -101.99% |
| 2023 Q2 | -7.69 Million SEK | 43.99% |
| 2022 Q3 | 3.98 Million SEK | 175.32% |
| 2022 FY | -19.2 Million SEK | -226.62% |
| 2022 Q1 | -5.48 Million SEK | -109.61% |
| 2022 Q2 | -5.28 Million SEK | 3.66% |
| 2022 Q4 | -27.67 Million SEK | -795.32% |
| 2021 Q2 | 190 Thousand SEK | -95.75% |
| 2021 Q1 | 4.46 Million SEK | 116.13% |
| 2021 Q3 | -226 Thousand SEK | -218.95% |
| 2021 Q4 | 57.07 Million SEK | 25355.12% |
| 2021 FY | 15.16 Million SEK | 81.98% |
| 2020 Q3 | 2.67 Million SEK | 23.69% |
| 2020 Q2 | 2.16 Million SEK | -46.75% |
| 2020 Q1 | 4.05 Million SEK | 28.25% |
| 2020 FY | 8.33 Million SEK | -39.7% |
| 2020 Q4 | -27.7 Million SEK | -1136.45% |
| 2019 Q3 | 7.05 Million SEK | 124.74% |
| 2019 Q4 | 3.16 Million SEK | -55.12% |
| 2019 FY | 13.81 Million SEK | 181.73% |
| 2019 Q1 | 1.63 Million SEK | 138.57% |
| 2019 Q2 | 3.13 Million SEK | 91.87% |
| 2018 Q1 | 50 Thousand SEK | 101.78% |
| 2018 FY | -16.9 Million SEK | -79.72% |
| 2018 Q4 | -4.23 Million SEK | 43.52% |
| 2018 Q3 | -7.5 Million SEK | 0.0% |
| 2018 Q2 | - SEK | -100.0% |
| 2017 Q1 | 745 Thousand SEK | 136.7% |
| 2017 FY | -9.4 Million SEK | -29.77% |
| 2017 Q4 | -2.8 Million SEK | -29.36% |
| 2017 Q3 | -2.16 Million SEK | 10.75% |
| 2017 Q2 | -2.42 Million SEK | -426.04% |
| 2016 Q1 | -1.1 Million SEK | 0.0% |
| 2016 FY | -7.25 Million SEK | 0.0% |
| 2016 Q4 | -2.03 Million SEK | 5.05% |
| 2016 Q3 | -2.13 Million SEK | -8.2% |
| 2016 Q2 | -1.97 Million SEK | -78.66% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 86.75% |
| Ziccum AB (publ) | -23.28 Million SEK | 8.569% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 106.148% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 150.951% |
| Mendus AB (publ) | 28.48 Million SEK | 174.738% |
| Genovis AB (publ.) | 54 Million SEK | 139.426% |
| Intervacc AB (publ) | -13.79 Million SEK | -54.347% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 1080.686% |
| Active Biotech AB (publ) | -1.67 Million SEK | -1171.086% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 313.698% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 179.381% |
| Aptahem AB (publ) | 2.63 Million SEK | 909.332% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -522.353% |
| Kancera AB (publ) | -1.96 Million SEK | -983.496% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 27750.243% |
| Fluicell AB (publ) | 1.73 Million SEK | 1325.011% |
| Saniona AB (publ) | 11.78 Million SEK | 280.721% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -316.078% |
| Biovica International AB (publ) | 6.87 Million SEK | 409.593% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 8.557% |
| AcouSort AB (publ) | 8.38 Million SEK | 353.793% |
| Xintela AB (publ) | 78 Thousand SEK | 27395.753% |
| Abliva AB (publ) | -35.66 Million SEK | 40.3% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 85.507% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 858.485% |
| OncoZenge AB (publ) | 3000.00 SEK | 709789.567% |
| Amniotics AB (publ) | -1.93 Million SEK | -1003.144% |
| 2cureX AB (publ) | -37.48 Million SEK | 43.205% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -4933.259% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 101.884% |
| Camurus AB (publ) | 1.58 Billion SEK | 101.347% |
| Corline Biomedical AB | 28.38 Million SEK | 175.02% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 82.653% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 38.135% |
| I-Tech AB | 27.56 Million SEK | 177.235% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 130.008% |
| Cyxone AB (publ) | 2.61 Million SEK | 915.423% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 725.645% |
| Biosergen AB | -456 Thousand SEK | -4569.01% |
| Cantargia AB (publ) | -3.45 Million SEK | -516.943% |
| NextCell Pharma AB | -43.74 Million SEK | 51.334% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -131.572% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 289.786% |
| Nanologica AB (publ) | -76 Thousand SEK | -27914.062% |
| SynAct Pharma AB | -778 Thousand SEK | -2636.592% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -10931.444% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | -64.763% |
| Lipum AB (publ) | 53 Thousand SEK | 40271.108% |
| BioInvent International AB (publ) | 71.46 Million SEK | 129.793% |
| Alzinova AB (publ) | 19.87 Million SEK | 207.128% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 158.654% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 1555.256% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -141837.913% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 1384.119% |
| Simris Alg AB (publ) | 2 Million SEK | 1160.821% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -494.712% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 160.164% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -1929.617% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 779.562% |